

**Table 2:** Characteristics of registry participants diagnosed between 2016 and 2019 by primary treatment received. Median (IQR) or n (column %). n=128 with other or unknown treatment.

	All participants (n=5,858)	Surgery (n=2,101)	Radiation therapy (n=1346)	ADT +/- chemother- apy (n=651)	AS or WW (n=1,632)
<b>Age at diagnosis, years</b>	67 (62–72)	65 (60–69)	69 (64–74)	76 (69–81)	67 (62–71)
<b>Ethnicity</b>					
European	5,099 (87)	1,865 (89)	1,144 (85)	543 (83)	1,444 (88)
Māori	411 (7.0)	100 (4.8)	131 (9.7)	64 (9.8)	104 (6.4)
Pacific Islander	119 (2.0)	37 (1.8)	24 (1.8)	21 (3.2)	34 (2.1)
Other	186 (3.2)	77 (3.7)	39 (2.9)	17 (2.6)	45 (2.8)
Unknown	43 (0.7)	22 (1.0)	8 (0.6)	6 (0.9)	5 (0.3)
<b>PSA at diagnosis, ng/ml *</b>	7.3 (5.3–12.3)	6.4 (5.0–9.2)	9.4 (6.2–15.2)	31.9 (15.4–100)	6.0 (4.8–8.5)
<b>Clinical T-stage</b>					
cT1	2,956 (50)	1,153 (55)	566 (42)	88 (14)	1,110 (68)
cT2	1,356 (23)	528 (25)	446 (33)	165 (25)	190 (12)
cT3/4	496 (8.5)	61 (2.9)	192 (14)	224 (34)	11 (0.7)
cTX	1,050 (18)	359 (17)	142 (11)	174 (27)	321 (20)
<b>ISUP Grade Group</b>					
1	2,030 (35)	405 (19)	172 (13)	22 (3.4)	1,408 (86)
2	1,622 (28)	904 (43)	469 (35)	52 (8.0)	150 (9.2)
3	821 (14)	411 (20)	273 (20)	86 (13)	38 (2.3)
4	608 (10)	219 (10)	212 (16)	141 (22)	21 (1.3)
5	682 (12)	152 (7.2)	213 (16)	293 (45)	11 (0.7)
Not recorded	95 (1.6)	10 (0.5)	7 (0.5)	57 (8.8)	4 (0.2)
<b>NCCN risk category</b>					
Low	1,581 (27)	335 (16)	112 (8.3)	9 (1.4)	1,116 (68)
Intermediate	2,243 (38)	1,259 (60)	614 (46)	40 (6.1)	280 (17)
High/Very High	1,194 (20)	409 (19)	442 (33)	239 (37)	82 (5.0)
Regional (cN1)	178 (3.0)	28 (1.3)	90 (6.7)	53 (8.1)	0
Metastatic	385 (6.6)	12 (0.6)	54 (4.0)	308 (47)	2 (0.1)
Not recorded	277 (4.7)	58 (2.8)	34 (2.5)	2 (0.3)	152 (9.3)

\* 350 no recorded PSA. ADT = androgen deprivation therapy. AS = active surveillance. ISUP = International Society of Urological Pathology. NCCN = National Comprehensive Cancer Network. PSA = prostate specific antigen. WW = watchful waiting.